The largest real-world safety study of semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, found no sign that the drug raises pancreatic cancer risk.
Researchers compared nearly 100,000 people who started semaglutide with a similar group who started other type 2 diabetes drugs. The rate of pancreatic cancer was essentially the same in both groups.
The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan in September 2026.
The work was a post-authorization safety study required by European regulators under Novo Nordisk's risk management plan for semaglutide.
Also read: Do magnesium supplements actually help you sleep? Here's what the evidence says
Where the pancreatic cancer worry came from
Pancreatic cancer has shadowed the GLP-1 class since 2013, when the US Food and Drug Administration flagged possible pancreatic toxicity in these drugs based on tissue samples from deceased patients.
The FDA called the association unproven and did not pull the drugs from the market, but the concern stuck to the label.
GLP-1 drugs still carry warnings about acute pancreatitis, an inflammation of the pancreas that can be serious. Because pancreatic cancer is aggressive and often caught late, even a small increase in risk would matter to the millions of Americans now on these drugs.
The Wegovy pill alone crossed three million US prescriptions in the five months after its January 2026 launch, on top of continued injection use.
Also read: How to get more iron from plant foods: the pairings that make a real difference
What the Nordic study actually found
Anton Pottegård of the University of Southern Denmark led the team. They matched 97,464 new semaglutide users with a similar number of patients starting insulin, a sulfonylurea, or an SGLT2 inhibitor.
Both groups were then tracked through the nationwide health registries of Denmark, Sweden, and Norway.
The semaglutide group accumulated about 167,000 person-years of follow-up. During that time, 131 people were diagnosed with pancreatic cancer. In the comparator group, the number was 123.
The pooled hazard ratio came out at 0.91. The confidence interval crossed 1.00, meaning semaglutide users were no more, and no less, likely to be diagnosed than patients on the older diabetes drugs.
Also read: Aged cheese, wheat germ and mushrooms are linked to longer life
The result held when the researchers looked at higher cumulative doses and longer treatment durations. More of the drug did not mean more cancer.
Pottegård said the study found no increased pancreatic cancer risk among semaglutide users compared with patients on other diabetes drugs used at a similar stage of treatment.
Consistent with other recent evidence
The Nordic findings line up with a June 2026 meta-analysis in Diabetes, Obesity and Metabolism. That analysis pooled six randomized trials of semaglutide covering 38,057 participants.
It also found no significant effect on pancreatic cancer risk, with an odds ratio of 0.78.
Also read: Want to age healthier? These habits can make a difference
Registry studies of this type cannot prove semaglutide is completely safe on this measure. Pancreatic cancers can take a decade or more to develop, so the current follow-up window is still short. Continued safety monitoring by regulators is standard for a drug used this widely.
Also read: What your baby eats in the first year could affect whether they develop eczema
This article is made and published by Mie Hermansen, who may have used AI in the preparation.